Switch to:
Also traded in: Brazil, France, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ABBV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ABBV Guru Trades in Q1 2016

Lee Ainslie 43,170 sh (New)
Joel Greenblatt 645,835 sh (+216.32%)
Jim Simons 1,563,056 sh (+168.22%)
David Dreman 30,542 sh (+16.28%)
Pioneer Investments 1,261,434 sh (+9.68%)
NWQ Managers 781,850 sh (+3.64%)
Scott Black 41,959 sh (+2.85%)
Jeff Auxier 20,572 sh (+1.48%)
Larry Robbins 13,686,588 sh (+1.05%)
Mairs and Power 268,191 sh (+0.52%)
Murray Stahl 36,154 sh (+0.37%)
Robert Bruce 232,915 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 1,225,000 sh (unchged)
Louis Moore Bacon Sold Out
John Paulson Sold Out
Dodge & Cox 33,232 sh (-0.07%)
PRIMECAP Management 1,022,845 sh (-12.21%)
Mario Gabelli 35,460 sh (-12.66%)
Ken Fisher 743,284 sh (-20.51%)
First Pacific Advisors 56,050 sh (-25.76%)
Tom Russo 21,718 sh (-74.96%)
Paul Tudor Jones 4,100 sh (-87.55%)
» More
Q2 2016

ABBV Guru Trades in Q2 2016

Manning & Napier Advisors, Inc 159,258 sh (New)
Stanley Druckenmiller 1,324,920 sh (New)
Joel Greenblatt 905,598 sh (+40.22%)
Lee Ainslie 50,540 sh (+17.07%)
Pioneer Investments 1,281,950 sh (+1.63%)
Jeff Auxier 20,672 sh (+0.49%)
Mairs and Power 269,153 sh (+0.36%)
Dodge & Cox 33,232 sh (unchged)
Robert Bruce 232,915 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 1,225,000 sh (unchged)
First Pacific Advisors Sold Out
Paul Tudor Jones Sold Out
Mario Gabelli 35,296 sh (-0.46%)
Murray Stahl 34,755 sh (-3.87%)
PRIMECAP Management 979,845 sh (-4.20%)
Scott Black 40,138 sh (-4.34%)
Ken Fisher 693,394 sh (-6.71%)
Larry Robbins 12,454,488 sh (-9.00%)
Tom Russo 17,106 sh (-21.24%)
Jim Simons 1,217,600 sh (-22.10%)
NWQ Managers 562,288 sh (-28.08%)
David Dreman 15,897 sh (-47.95%)
» More
Q3 2016

ABBV Guru Trades in Q3 2016

Paul Tudor Jones 8,900 sh (New)
Jim Simons 1,918,456 sh (+57.56%)
Murray Stahl 35,056 sh (+0.87%)
Stanley Druckenmiller 1,324,920 sh (unchged)
Dodge & Cox 33,232 sh (unchged)
Tom Russo 17,106 sh (unchged)
Robert Bruce 232,915 sh (unchged)
Jeff Auxier 20,622 sh (-0.24%)
Mairs and Power 266,453 sh (-1.00%)
Manning & Napier Advisors, Inc 157,543 sh (-1.08%)
Ken Fisher 684,042 sh (-1.35%)
Lee Ainslie 49,600 sh (-1.86%)
PRIMECAP Management 953,845 sh (-2.65%)
David Dreman 15,019 sh (-5.52%)
Scott Black 36,748 sh (-8.45%)
Pioneer Investments 1,130,994 sh (-11.78%)
Joel Greenblatt 684,356 sh (-24.43%)
Mario Gabelli 20,196 sh (-42.78%)
Larry Robbins 6,030,141 sh (-51.58%)
NWQ Managers 146,743 sh (-73.90%)
Eaton Vance Worldwide Health Sciences Fund 742,955 sh (-39.35%)
» More
Q4 2016

ABBV Guru Trades in Q4 2016

Richard Pzena 3,476 sh (New)
Steven Cohen 1,136,566 sh (New)
David Dreman 22,908 sh (+52.53%)
Larry Robbins 9,116,969 sh (+51.19%)
Joel Greenblatt 935,437 sh (+36.69%)
Scott Black 37,816 sh (+2.91%)
Lee Ainslie 50,920 sh (+2.66%)
Manning & Napier Advisors, Inc 160,726 sh (+2.02%)
Ken Fisher 696,569 sh (+1.83%)
Robert Bruce 232,915 sh (unchged)
Tom Russo 17,106 sh (unchged)
Dodge & Cox 33,232 sh (unchged)
NWQ Managers Sold Out
Mario Gabelli 20,076 sh (-0.59%)
Mairs and Power 264,365 sh (-0.78%)
Murray Stahl 33,854 sh (-3.43%)
PRIMECAP Management 901,845 sh (-5.45%)
Stanley Druckenmiller 1,221,723 sh (-7.79%)
Paul Tudor Jones 4,900 sh (-44.94%)
Jim Simons 350,800 sh (-81.71%)
Pioneer Investments 112,829 sh (-90.02%)
Eaton Vance Worldwide Health Sciences Fund 690,536 sh (-7.06%)
» More
» Details

Insider Trades

Latest Guru Trades with ABBV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 5122
Compare:OTCPK:GLAXF, OTCPK:BAYZF, NYSE:BMY, NYSE:SNY, NYSE:LLY, NYSE:AZN, OTCPK:ALPMY, OTCPK:OTSKY, NYSE:MRK, OTCPK:NVSEF, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:CHJTF, OTCPK:SNPHY, OTCPK:PTKFY, OTCPK:GWPRF, NAS:HCM, OTCPK:MAYNF » details
Traded in other countries:ABBV34.Brazil, ABBV.France, 4AB.Germany, ABBV.Mexico, ABBV.Switzerland, 0QCV.UK,
AbbVie Inc is a research-based biopharmaceutical company. Its products are used to treat diseases including rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis complications.

AbbVie Inc is a research-based biopharmaceutical company incorporated in Delaware on April 10, 2012. The Company is engaged in the discovery, development, manufacture and sale of a broad line of pharmaceutical products. It develops and markets therapies that address some of the world's complex and serious diseases. It products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. It also has a pipeline of new medicines, including more than 50 compounds or indications in clinical development across such important medical specialties as immunology, virology/liver disease, oncology, neurological diseases and women's health. The Company's products offering includes HUMIRA, IMBRUVICA, VIEKIRA, Creon, Synagis, Lupron, Synthroid, Kaletra, AndroGel, Sevoflurane, Duodopa, Dyslipidemia products, and other products. The Company's products are sold directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from AbbVie-owned distribution centers and public warehouses. The Company faces competition from other research-based pharmaceuticals and biotechnology companies that discover, manufacture, market, and sell proprietary pharmaceutical products and biologics. The manufacture, marketing, sale, promotion, and distribution of AbbVie's products are subject to comprehensive government regulation.

Top Ranked Articles about AbbVie Inc

AbbVie's Hepatitis C Treatment Under FDA Review Treatment is supported by multiple studies
AbbVie Inc. (NYSE:ABBV) announced Thursday through the PR Newswire that the U.S. Food & Drug Administration validated its New Drug Application (NDA) for its “investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P).” Read more...
AbbVie to Start Study on Alzheimer's Treatment The treatment is aimed at early-onset Alzheimer's disease
AbbVie Inc. (NYSE:ABBV) announced on Jan. 25 the beginning of two studies to assess 8E12's efficacy and safety in people with early-onset Alzheimer's disease and PSP patients. Read more...
AbbVie Reports 4th-Quarter 2016 Results Company misses revenue, matches earnings
AbbVie Inc. (NYSE:ABBV) closed fourth-quarter 2016 reporting EPS of $1.20, 0.82% lower than third-quarter 2016 EPS of $1.21 and 6.2% higher than fourth-quarter 2015. Read more...
AbbVie's Hepatitic C Treatment Under Accelerated Review by EMA Treatment is still waiting for FDA approval
 AbbVie Inc. (NYSE:ABBV) announced Tuesday through the PR Newswire that the European Medicines Agency has validated its marketing authorization application. The company's application seeks permission to rapidly bring its “investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P)” to the market. Read more...
AbbVie Increases Price of Humira Analysts see a 15% upside for the stock
As reported by Barron’s, AbbVie (NYSE:ABBV) increased the price of Humira by 8.4% last Friday. Humira is the pharmaceutical company's most profitable product and its sales account for more than 60% of the total sales. Read more...
AbbVie Gets FDA Approval for Lymphoma Drug Drug had 46% efficacy rate in clinical trial
AbbVie Inc. (NYSE:ABBV) announced on Jan. 19 that its drug IMBRUVICA (ibrutinib) received the approval from the FDA as a therapy for patients affected with marginal zone lymphoma (MZL). Read more...
Boehringer Ingelheim's Humira Biosimilar Under Review by EMA, FDA AbbVie's flagship drug faces increasing competition from biosimilars
Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies, announced Wednesday through the PR Newswire that its BI 695501, a biosimilar of AbbVie Inc.'s (NYSE:ABBV) Humira (adalimumab), has been accepted for regulatory review by the European Medicines Agency and the U.S. Food and Drug Administration. Read more...
Entana Pharmaceuticals Releases Study Results of Hepatitis Treatment in Japanese Patients Japan has one of the highest rates of hepatitis C in the industrialized world
Enanta Pharmaceuticals Inc. (NASDAQ:ENTAannounced on Monday the results of the Phase 3 CERTAIN-1 study done in collaboration with AbbVie (NYSE:ABBV) that assessed the safety and efficacy of AbbVie’s investigational regimen of glecaprevir/pibrentasvir (G/P) in Japanese patients infected with genotype 1 chronic hepatitis C virus without cirrhosis. Read more...
Galapagos NV Announces Results From Cystic Fibrosis Treatment Study Researchers observed a decline in sweat chloride concentration
Galapagos NV (NASDAQ:GLPG), the Belgian clinical-stage biotechnology company that collaborated with AbbVie Inc. (NYSE:ABBV) on a treatment for patients affected with cystic fibrosis, announced last week the “topline results from its SAPHIRA 1 Phase 2 study in cystic fibrosis patients with potentiator GLPG1837.” Read more...
AbbVie Files for Approval of Hepatitis C Treatment in the US The application is backed by relevant results and the company will apply in Europe in the first quarter of 2017
AbbVie (NYSE:ABBV) announced today through PRNewswire that it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration for its “investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P).” Read more...

Ratios

vs
industry
vs
history

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.80
ABBV's Dividend Yield is ranked higher than
88% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.61 vs. ABBV: 3.80 )
Ranked among companies with meaningful Dividend Yield only.
ABBV' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0 Max: 3.8
Current: 3.8
0
3.8
Dividend Payout 0.60
ABBV's Dividend Payout is ranked higher than
82% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.36 vs. ABBV: 0.60 )
Ranked among companies with meaningful Dividend Payout only.
ABBV' s Dividend Payout Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.6
Current: 0.6
0
0.6
Forward Dividend Yield 4.14
ABBV's Forward Dividend Yield is ranked higher than
90% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.35 vs. ABBV: 4.14 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.80
ABBV's Yield on cost (5-Year) is ranked higher than
74% of the 764 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.14 vs. ABBV: 3.80 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ABBV' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 3.8

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $25,638
EPS (TTM) $ 3.63
Beta1.47
Short Percentage of Float1.92%
52-Week Range $53.35 - 68.12
Shares Outstanding (Mil)1,625.10

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 27,742 29,890 31,924
EPS ($) 5.37 6.38 7.31
EPS w/o NRI ($) 5.37 6.38 7.31
EPS Growth Rate
(3Y to 5Y Estimate)
5.73%
Dividends Per Share ($) 2.52 2.66 2.77
» More Articles for ABBV

Headlines

Articles On GuruFocus.com
Galapagos NV Tests Cystic Fibrosis Treatment on First Patient Feb 03 2017 
AbbVie's Hepatitis C Treatment Under FDA Review Feb 02 2017 
Is Abbott Labs or AbbVie the Better Investment? Jan 31 2017 
AbbVie to Start Study on Alzheimer's Treatment Jan 29 2017 
AbbVie Reports 4th-Quarter 2016 Results Jan 27 2017 
AbbVie's Hepatitic C Treatment Under Accelerated Review by EMA Jan 24 2017 
Abbott Laboratories: An Undervalued Diamond in Overvalued Markets Jan 24 2017 
AbbVie Increases Price of Humira Jan 23 2017 
AbbVie Gets FDA Approval for Lymphoma Drug Jan 22 2017 
Boehringer Ingelheim's Humira Biosimilar Under Review by EMA and FDA Jan 19 2017 

More From Other Websites
ABBVIE INC. Files SEC form 10-K, Annual Report Feb 17 2017
Parsabiv Is Expected to Boost Amgen’s Revenues in 2017 Feb 17 2017
Pfizer's Xeljanz Combo Comparable to AbbVie's Humira Feb 17 2017
AbbVie Announces $5 Billion Increase to Stock Repurchase Program Feb 17 2017
NICE Rejects AbbVie’s Leukemia Drug Venclexta Feb 16 2017
UK National Institute For Health And Care Excellence Rejects Leukemia Drug From AbbVie Inc (ABBV) Feb 16 2017
AbbVie Declares Quarterly Dividend Feb 16 2017
Pfizer says rheumatoid arthritis drug is comparable to Humira as combination treatment but not alone Feb 16 2017
Eli Lilly Is Great Stock to Buy Now Feb 15 2017
AbbVie to Present at the Cowen and Company 37th Annual Health Care Conference Feb 15 2017
These drug and medical device companies made the most payments to N.Y.C. hospitals Feb 14 2017
10 Best Dividend-Paying Stocks for 2017 Feb 09 2017
Finding the Best Value Investment in Healthcare Feb 08 2017
The Zacks Analyst Blog Highlights: Apple, Visa and AbbVie Feb 08 2017
Gilead 2017 hepatitis C sales forecast disappoints, shares drop Feb 07 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)